» Articles » PMID: 33996049

Management of Patients with BRCA Mutation from the Point of View of a Breast Surgeon

Overview
Publisher Wolters Kluwer
Specialty Medical Education
Date 2021 May 17
PMID 33996049
Citations 2
Authors
Affiliations
Soon will be listed here.
Abstract

Germ-line mutation in BRCA (BReast CAncer gene) 1 or BRCA2 are found in 3-4% of all women with breast cancer. These patients have a significant increased risk of breast and ovarian cancer. They are often younger when diagnosed with the mutation, and the possible breast cancer they get is often aggressive with inferior outcome. There are risk reducing strategies, and the most powerful strategy is risk reducing surgery, both risk reducing bilateral mastectomy (RRM) and risk reducing bilateral salpino-oophorectomy (PBSO). This review is meant to address breast surgery in patients with germline BRCA mutation. The guidelines and techniques applied is under continuous change and it is important for the clinicians to be well informed to provide the patient with the information needed for them to make an informed decision on what risk strategy to choose.

Citing Articles

Prophylactic Risk-Reducing Mastectomy (PRRM): A Set Practice or Catch-22 Situation in LMIC. A Single-Centre Prospective Cohort Study.

Mooghal M, Vohra L, Khan W, Akbar F World J Surg. 2023; 47(9):2154-2160.

PMID: 37145137 DOI: 10.1007/s00268-023-07033-1.


'Breast Cancer Resistance Likelihood and Personalized Treatment Through Integrated Multiomics'.

Mehmood S, Faheem M, Ismail H, Farhat S, Ali M, Younis S Front Mol Biosci. 2022; 9:783494.

PMID: 35495618 PMC: 9048735. DOI: 10.3389/fmolb.2022.783494.

References
1.
Nomikos A, Husain E, Graham A . Occult disease in reduction mammoplasties and prophylactic mastectomies. Breast J. 2019; 26(4):691-696. DOI: 10.1111/tbj.13512. View

2.
Chang D . Breast Reconstruction with Microvascular MS-TRAM and DIEP Flaps. Arch Plast Surg. 2012; 39(1):3-10. PMC: 3385301. DOI: 10.5999/aps.2012.39.1.3. View

3.
Filho A, Carvalho G, Sena L, Gomes L, Valerio M, Martins R . Hormone therapy after risk-reducing surgery in patients with BRCA1/BRCA2 mutation: evaluation of potential benefits and safety. Rev Assoc Med Bras (1992). 2020; 66(8):1134-1138. DOI: 10.1590/1806-9282.66.8.1134. View

4.
Broeks A, Braaf L, Huseinovic A, Nooijen A, Urbanus J, Hogervorst F . Identification of women with an increased risk of developing radiation-induced breast cancer: a case only study. Breast Cancer Res. 2007; 9(2):R26. PMC: 1868917. DOI: 10.1186/bcr1668. View

5.
Byrski T, Gronwald J, Huzarski T, Grzybowska E, Budryk M, Stawicka M . Pathologic complete response rates in young women with BRCA1-positive breast cancers after neoadjuvant chemotherapy. J Clin Oncol. 2009; 28(3):375-9. DOI: 10.1200/JCO.2008.20.7019. View